Related Experiment Video

Updated: May 13, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Three novel human sporadic melanoma cell lines: signaling pathways controlled by MC1R, BRAF and β-catenins

P Zanna1, I Maida, C Grieco

  • 1Dept. of Basic Medical Sciences, University of Bari, Italy.

Journal of Biological Regulators and Homeostatic Agents
|March 16, 2013
PubMed

Insights

Novel melanoma cell lines with BRAF mutations show impaired MC1R signaling and altered beta-catenin localization. These findings offer new insights into melanoma pathogenesis and potential therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Melanoma pathogenesis involves complex cell signaling pathways.
  • MC1R, BRAF, NRAS, and beta-catenin are critical in melanoma development.
  • Characterization of novel melanoma cell lines is essential for understanding disease mechanisms.

Purpose of the Study:

  • To investigate the behavior of three novel human sporadic melanoma cell lines (hmel1, hmel9, hmel11).
  • To analyze cell signaling pathways involving MC1R, BRAF, NRAS, and beta-catenin in these cell lines.
  • To compare novel cell lines with established metastatic melanoma cell lines (HBL, LND1).

Main Methods:

  • Culturing and characterization of novel human sporadic melanoma cell lines.
  • Sequencing of MC1R, BRAF, and beta-catenin genes.
  • Analysis of ERK phosphorylation and beta-catenin localization.
  • Pharmacological inhibition of the MEK pathway using PD98059.

Main Results:

  • Novel cell lines exhibit BRAF mutations (V600) leading to constitutive ERK phosphorylation, despite intact MC1R.
  • MC1R signaling is impaired in novel cell lines, showing unresponsiveness to NDP-MSH treatment.
  • Beta-catenin levels are reduced in novel cell lines, with altered localization (plasma membrane/cytoplasm) compared to controls (cytoplasm/nucleus).
  • Beta-catenin mutations were identified in HBL, LND1, and hmel1, but not in hmel9 and hmel11.
  • The RAS/RAF/MAPK pathway did not influence beta-catenin stability or localization.

Conclusions:

  • Novel melanoma cell lines possess distinct signaling profiles characterized by BRAF mutations and altered beta-catenin.
  • BRAF mutations drive melanoma phenotypes independently of MC1R status in these lines.
  • Beta-catenin dysregulation in melanoma is not solely dependent on the RAS/RAF/MAPK pathway.
  • These cell lines serve as valuable models for studying melanoma progression and therapeutic strategies.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...